Abstract
Background
The study of the clinical features of multiple primary cancers (MPC) may provide insight into the pathogenesis of specific cancers, as well as the issue of treatment-related induction of second tumors.
Methods
Between 1972 and 1995, 94 of 765 patients with urologic cancer treated at our hospital had MPC. We retrospectively analyzed the clinical features of these patients, and compared them with those of the 671 patients with single primary cancers (SPC).
Results
The frequency of MPC among all 765 patients was 12.3%. The average age at diagnosis of urologic cancer in the male patients was significantly higher in the MPC group than in the SPC group. In the MPC group, the organs most commonly involved were the bladder and prostate (urologic cancers), and the stomach and lung (nonurologic cancers). Adenocarcinoma was the most common tumor in the MPC group. The interval between the first and second cancer diagnoses was significantly longer in female patients with MPC than in male patients. No significant difference between the MPC and SPC groups was observed in the distribution of ABO blood groups or in the frequency of history of tobacco or alcohol use. Four MPC patients had second cancers considered to have been induced by the treatment for the first cancer. The prognoses were significantly poorer for the patients with MPC. The rate of death due to urologic cancer was much lower in the patients with MPC than in those with SPC.
Conclusions
We found that more than 10% of the 765 patients with urologic cancer whose cases we reviewed had another primary cancer. Because the number of cases of MPC is increasing, it is important to be aware of the possibility of the development of MPC and to therefore carefully follow up cancer patients.
Similar content being viewed by others
References
Matzkin H, Braf Z. Multiple primary malignant neoplasms in the genitourinary tract: occurrence and etiology. J Urol 1989;142:1–12.
Dieckmann KP, Wegner HEH, Krain J. Multiple primary neoplasms in patients with testicular germ cell tumor. Oncology 1994;51:450–458.
Warren S, Gates O. Multiple primary malignant tumors: a survey of the literature and a statistical study. Am J Cancer 1932;16:1358–1414.
Wegner HEH. Multiple primary cancers in urologic patients: audit of 19-year experience in Berlin and review of the literature. Urology 1992;39:231–236.
Boffetta P, Kaldor JM. Secondary malignancies following cancer chemotherapy. Acta Oncol 1994;33:591–598.
Kakizaki H, Abe Y, Sugano O, Kato H. A hundred cases of multiple primary neoplasms in association with genitourinary cancer. Jpn J Urol 1992;83:1841–1846 (in Japanese).
Takahashi S, Sugimoto M, Shinohara M, Kinoshita K. Clinical analysis of multiple primary cancers associated with bladder cancer. Jpn J Urol 1992;83:1118–1123 (in Japanese).
Kakizoe T, Matsumoto K, Nishino Y, Ohtani M. Double cancer observed from bladder cancer. Jpn J Clin Urol 1983;37:805–809 (in Japanese).
Fujimoto I, Hanai A, Oshima A, Hiyama T, Tsukuma H, Murakami R, Sobue T, Tanaka H, Ajiki W. Incidence and mortality statistics. In: Fujimoto I, Hanai A, Hiyama T, Tsukuma H, Takasugi Y, Sugaya T (eds) Cancer incidence and mortality in Osaka 1963–1989. Tokyo: Shinohara Publishing, 1993:49–214.
Bokemeyer BC, Schmoll HJ. Treatment of testicular cancer and the development of secondary malignancies. J Clin Oncol 1995;13:283–292.
Bokemeyer BC, Schmoll HJ. Secondary neoplasms following treatment of malignant germ cell tumor. J Clin Oncol 1993;11:1703–1709.
Doll R, Peto R. The cause of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 1981;66:1192–1308.
Wynder EL, Gori GB. Contribution of the environment to cancer incidence: an epidemiologic exercise. J Natl Cancer Inst 1977;58:825–832.
Day GL, Shore RE, Blot WJ, McLaughlin JK, Austin DF, Greeenberg RS, Liff JM, Preston-Martin S, Sarkar S, Schoenberg JB, Fraumeni JF. Dietary factors and second primary cancers: a follow-up of oral and pharyngeal cancer patients. Nutr Cancer 1994;21:223–232.
Gallo O, Bianchi S. p53 expression: a potential biomarker for risk of multiple primary malignancies in the upper aerodigestive tract. Oral Oncol Eur J Cancer 1995;31:53–57.
Spits MR, Hoque A, Trizna Z, Schantz SP, Amos CI, King TM, Bondy ML, Hong WK, Hsu TC. Mutagen sensitivity as a risk factor for second malignant tumors following malignancies of the upper aerodigestive tract. J Natl Cancer Inst 1994;86:1681–1684.
Shah S, Evans DGR, Blair V, Burnell LD, Birch JM. Assessment of relative risk of second primary tumors after ovarian cancer and of the usefulness of double primary cases as a source of material for genetic studies with a cancer registry. Cancer 1993;72:819–827.
Horii A, Han HJ, Shimada M, Yanagisawa A, Kato Y, Ohta H, Yasui W, Tahara E, Nakamura Y. Frequent replication errors at microsatellite loci in tumors of patients with multiple primary cancers. Cancer Res 1994;54:3373–3375.
Shimada M, Horii A, Sasaki S, Yanagisawa A, Kato Y, Yamashita K, Okagawa K, Yamasaki K, Ishiguro S, Inoue M, Shiozaki H, Nakamura Y. Infrequent replication errors at microsatellite loci in tumors of patients with multiple primary cancers of the esophagus and various other tissues. Jpn J Cancer Res 1995;86:511–515.
Hoffman M, Roberts WS, Cavanagh D. Second pelvic malignancies following radiation therapy for cervical cancer. Obstet Gynecol Surv 1985;40:611–617.
Pettersson F, Fotiou S, Einhorn N, Silfversward C. Cohort study of the long-term effect of irradiation for carcinoma of the uterine cervix. Acta Radiol Oncol 1985;24:145–151.
Kleinerman RA, Curtis RE, Boice JD Jr, Flannery JT, Fraumeni JF Jr. Second cancers following radiotherapy for cervical cancer. J Natl Cancer Inst 1982;69:1027–1033.
Duncan RE, Bennett DW, Evans AT, Aron BS, Schellhas HF. Radiation-induced bladder tumors. J Urol 1977;118: 43–45.
Rosner F. Acute leukemia as a delayed consequence of cancer chemotherapy. Cancer 1976;37:1033–1036.
Harris CC. The carcinogenicity of anticancer drugs: a hazard in man. Cancer 1976;37:1014–1023.
Chabner BA. Second neoplasm—a complication of cancer chemotherapy. N Engl J Med 1977;297:213–215.
Kantor AF, McLaughlin JK. Second cancer following cancer of the urinary system in Connecticut, 1935–82. Natl Cancer Inst Monogr 1985;68:149–159.
Jensen OM, Knudsen JB, Sorensen BL. Second cancer following cancer of the urinary system in Denmark, 1943–80. Natl Cancer Inst Monogr 1985;68:349–360.
Wegner HEH, Meier T, Klan R, Dieckmann KP. Bladder cancer following prostate cancer—an analysis of risk factors. Int Urol Nephrol 1994;26:43–51.
Liscow AS, Neugut AI, Benson M, Olsson CA, Birkhoff J, Chang AC. Multiple primary neoplasms in association with prostate cancer in black and white patients. Cancer 1987;59:380–384.
Greenberg RS, Rustin ED, Clard WS. Risk of genitourinary malignancies after cancer of the prostate. Cancer 1988;61: 396–401.
Kleinerman RA, Liebermann JV, Li FP. Second cancer following cancer of the male genital system in Connecticut, 1935–82. Natl Cancer Inst Monogr 1985;68:139–147.
Osterlind A, Rorth M, Prener A. Second cancer following cancer of the male genital system in Denmark, 1943–80. Natl Cancer Inst Monogr 1985;68:341–347.
Author information
Authors and Affiliations
About this article
Cite this article
Nakata, S., Kato, Y., Sato, J. et al. Analysis of multiple primary cancers in patients with urologic cancer. Int J Clin Oncol 2, 40–46 (1997). https://doi.org/10.1007/BF02492596
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02492596